Human neutralizing antibodies elicited by SARS-CoV-2 infection

Cited by (1,008)

Items 301–400 of 1,008

1. Tackling COVID-19 with neutralizing monoclonal antibodies
   Corti, Davide, Purcell, Lisa A., Snell, Gyorgy, Veesler, David · 2021 · Cell
2. Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers
   E. Rujas, I. Kucharska, Yong-Zi Tan, S. Benlekbir, H. Cui, Tian-Tian Zhao, G. Wasney, P. Budylowski, Furkan Guvenc, J. Newton et al. · 2021 · Nature Communications
3. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization
   Per Johan Klasse, John P. Moore · 2020 · eLife
4. Therapeutic Strategies Against COVID-19 and Structural Characterization of SARS-CoV-2: A Review
   Gi Uk Jeong, Hanra Song, Gun Young Yoon, Doyoun Kim, Young‐Chan Kwon · 2020 · Frontiers in Microbiology
5. Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
   Huan Ma, Weihong Zeng, Xiang-Zhi Meng, Xiaoxue Huang, Yunru Yang, Dan Zhao, Peigen Zhou, Xiao-Fang Wang, Chang-Cheng Zhao, Yong-Jun Sun et al. · 2021 · Journal of Virology
6. Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents
   Nina Koerber, Alina Priller, Sarah Yazici, Tanja Bauer, Cho‐Chin Cheng, Hrvoje Mijočević, Hannah Wintersteller, Samuel D. Jeske, Emanuel Vogel, Martin Feuerherd et al. · 2022 · Nature Communications
7. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients
   Xavier Charmetant, Maxime Espi, Iliès Benotmane, Véronique Barateau, Françoise Heibel, Fanny Buron, Gabriela Gautier-Vargas, Marion Delafosse, Peggy Perrin, Alice Koenig et al. · 2022 · Science Translational Medicine
8. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
   Henning Gruell, Kanika Vanshylla, Michael Korenkov, Pinkus Tober‐Lau, Matthias Zehner, Friederike Münn, Hanna Janicki, Max Augustin, Philipp Schommers, Leif Erik Sander et al. · 2022 · Cell Host & Microbe
9. Advances in the design and development of SARS-CoV-2 vaccines
   Xue‐Liang Peng, Ji‐Si‐Yu Cheng, Hai‐Lun Gong, Meng-Di Yuan, Xiaohong Zhao, Zibiao Li, Dai‐Xu Wei · 2021 · Military Medical Research
10. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
    Shuang Wang, Yun Peng, Rongjuan Wang, Shasha Jiao, Min Wang, Weijin Huang, Chao Shan, Wen Jiang, Zepeng Li, Chunying Gu et al. · 2020 · Nature Communications
11. Approaches towards fighting the COVID‑19 pandemic (Review)
    Shih‐Chang Tsai, Chi‐Cheng Lu, DA-TIAN BAU, Yu‐Jen Chiu, Yu‐Ting Yen, Yuan‐Man Hsu, Chih‐Wei Fu, Sheng‐Chu Kuo, Yu‐Shiang Lo, Hong‐Yi Chiu et al. · 2020 · International Journal of Molecular Medicine
12. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia
    D. Asarnow, Bei Wang, W. Lee, Yuanyu Hu, Ching-Wen Huang, B. Faust, P. Ng, E. Ngoh, M. Bohn, D. Bulkley et al. · 2021 · Cell
13. COVID-19 Vaccines: Adenoviral Vectors
    Catherine Jacob-Dolan, Dan H. Barouch · 2021 · Annual Review of Medicine
14. The role of B cells in COVID-19 infection and vaccination
    Shiru Chen, Fei Guan, Fabio Candotti, Kamel Benlagha, Niels Olsen Saraiva Câmara, Andrés A. Herrada, Louisa Katherine James, Jiahui Lei, Heather Miller, Masato Kubo et al. · 2022 · Frontiers in Immunology
15. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
    Suryadevara, Naveenchandra, Shrihari, Swathi, Gilchuk, Pavlo, VanBlargan, Laura A., Binshtein, Elad, Zost, Seth J., Nargi, Rachel S., Sutton, Rachel E., Winkler, Emma S., Chen, Elaine C. et al. · 2021
16. Immunotherapeutic approaches to curtail COVID-19
    Hajar Owji, Manica Negahdaripour, Nasim Hajighahramani · 2020 · International Immunopharmacology
17. Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
    Renhong Yan, Ruoke Wang, Bin Ju, Jinfang Yu, Yuanyuan Zhang, Nan Liu, Jia Wang, Qi Zhang, Peng Chen, Bing Zhou et al. · 2021 · Cell Research
18. Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption
    Wenlin Ren, Jun Lan, Xiaohui Ju, Mingli Gong, Quanxin Long, Zihui Zhu, Yanying Yu, Jianping Wu, Jin Zhong, Rong Zhang et al. · 2021 · PLoS Pathogens
19. Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike
    Lihong Liu, Pengfei Wang, Manoj S. Nair, Jian Yu, Micah Rapp, Qian Wang, Yang Luo, Jasper F-W. Chan, Vincent Sahi, Amir Figueroa et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
20. Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation
    Xiaotian Tan, Mila Krel, Enriko Dolgov, Steven Park, Xuzhou Li, Weishu Wu, Yun‐Lu Sun, Jie Zhang, Maung Kyaw Khaing Oo, David S. Perlin et al. · 2020 · Biosensors and Bioelectronics
21. Targeted therapy strategies against SARS‐CoV‐2 cell entry mechanisms: A systematic review of in vitro and in vivo studies
    Simin Seyedpour, Behzad Khodaei, Amir Hossein Loghman, Nasrin Seyedpour, Misagh Fathi Kisomi, Maryam Balibegloo, Sasan Salehi Nezamabadi, Bahareh Gholami, Amene Saghazadeh, Nima Rezaei · 2020 · Journal of Cellular Physiology
22. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody
    Nicholas C. Wu, Meng Yuan, Sandhya Bangaru, Deli Huang, Xueyong Zhu, Chang-Chun David Lee, Hannah L. Turner, Linghang Peng, Linlin Yang, Dennis R. Burton et al. · 2020 · PLoS Pathogens
23. Severe COVID-19 and Sepsis: Immune Pathogenesis and Laboratory Markers
    Mai Mahmoud Zafer, Hadir A. El‐Mahallawy, Hossam M. Ashour · 2021 · Microorganisms
24. Evaluation of High-Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization Test
    Antonin Bal, Bruno Pozzetto, Mary‐Anne Trabaud, Vanessa Escuret, Muriel Rabilloud, Carole Langlois, Adèle Paul, Nicolas Guibert, Constance d’Aubarede, Amélie Massardier-Pilonchery et al. · 2021 · Clinical Chemistry
25. Breadth and function of antibody response to acute SARS-CoV-2 infection in humans
    Kuan-Ying A. Huang, T. Tan, Ting-Hua Chen, Chung-Guei Huang, R. Harvey, S. Hussain, Cheng-Pin Chen, Adam C. Harding, J. Gilbert-Jaramillo, Xu Liu et al. · 2021 · PLoS Pathogens
26. Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance
    Mohamed Fareh, Wei Dong Zhao, Wenxin Hu, Joshua M. L. Casan, Amit Kumar, Jori Symons, Jennifer M. Zerbato, Danielle Fong, Ilia Voskoboinik, Paul G. Ekert et al. · 2021 · Nature Communications
27. COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge
    Anna Furlan, Gabriella Forner, Ludovica Cipriani, Elisa Vian, Roberto Rigoli, Filíppo Gherlinzoni, Piergiorgio Scotton · 2021 · Frontiers in Immunology
28. Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations
    Gennady M. Verkhivker, Steve Agajanian, Deniz Yaşar Öztaş, Grace Gupta · 2021 · Biochemistry
29. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity
    S. Nielsen, Line K. Vibholm, Ida Monrad, R. Olesen, Giacomo S. Frattari, M. H. Pahus, J. F. Højen, J. Gunst, C. Erikstrup, Andreas Holleufer et al. · 2020 · bioRxiv
30. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
    Mingxi Li, Yifei Ren, Zhen Qin Aw, Bo Chen, Ziqing Yang, Yuqing Lei, Lin Cheng, Qingtai Liang, Junxian Hong, Yiling Yang et al. · 2022 · Nature Communications
31. Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
    Gabriele Cerutti, Yicheng Guo, Pengfei Wang, Manoj S. Nair, Maple Wang, Yaoxing Huang, Jian Yu, Lihong Liu, Phinikoula S. Katsamba, Fabiana A. Bahna et al. · 2021 · Cell Reports
32. Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies
    Qi Xiang, Linhao Li, Jie Wu, Miao Tian, Yang Fu · 2022 · Microbiological Research
33. Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2
    Cyril Planchais, Ignacio Fernández, Timothée Bruel, Guilherme Dias de Melo, Matthieu Prot, Maxime Beretta, Pablo Guardado‐Calvo, Jérémy Dufloo, Luis Manuel Molinos-Albert, Marija Backović et al. · 2022 · The Journal of Experimental Medicine
34. A rapid cell-free expression and screening platform for antibody discovery
    Andrew C. Hunt, Bastian Vögeli, Ahmed O. Hassan, Laura Guerrero, Weston Kightlinger, Danielle J. Yoesep, Antje Krüger, Madison A. DeWinter, Michael Diamond, Ashty S. Karim et al. · 2023 · Nature Communications
35. Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro
    Yang, Ren, Huang, Baoying, A, Ruhan, Li, Wenhui, Wang, Wenling, Deng, Yao, Tan, Wenjie · 2020 · Biosafety and Health
36. Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays
    Inesa Hyseni, Eleonora Molesti, Linda Benincasa, Pietro Piu, Elisa Casa, Nigel James Temperton, Alessandro Manenti, Emanuele Montomoli · 2020 · Viruses
37. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes
    Tongqing Zhou, I‐Ting Teng, Adam S. Olia, Gabriele Cerutti, Jason Gorman, Alexandra F. Nazzari, Wei Shi, Yaroslav Tsybovsky, Lingshu Wang, Shuishu Wang et al. · 2020 · Cell Reports
38. Severe acute respiratory syndrome‐coronavirus‐2 spike (S) protein based vaccine candidates: State of the art and future prospects
    Arash Arashkia, Somayeh Jalilvand, Nasir Mohajel, Atefeh Afchangi, Kayhan Azadmanesh, ‪Mostafa Salehi-Vaziri, Mehdi Fazlalipour, Mohammad Hassan Pouriayevali, Tahmineh Jalali, Seyed Dawood Mousavi Nasab et al. · 2020 · Reviews in Medical Virology
39. Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions
    Yue Zheng, Erin T. Larragoite, Juan Lama, Isabel Cisneros, Julio C. Delgado, Patricia R. Slev, Jenna Rychert, Emily A. Innis, Elizabeth S. C. P. Williams, Mayte Coiras et al. · 2021 · Virology Journal
40. SARS-CoV-2 reinfection and implications for vaccine development
    F. Nainu, R. S. Abidin, M. Bahar, A. Frediansyah, Talha Bin Emran, A. Rabaan, K. Dhama, H. Harapan · 2020 · Human Vaccines & Immunotherapeutics
41. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
    Drew Weissman, Mohamad‐Gabriel Alameh, Thushan I. de Silva, Paul Collini, Hailey R. Hornsby, Rebecca L. Brown, Celia C. LaBranche, Robert J. Edwards, Laura L. Sutherland, Sampa Santra et al. · 2020 · medRxiv
42. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development
    Daniela Cornelia Călina, Chandan Kumar Sarkar, Andreea Letiția Arsene, Bahare Salehi, Anca Oana Docea, Milon Mondal, Muhammad Torequl Islam, Alireza Zali, Javad Sharifi‐Rad · 2020 · Immunologic Research
43. Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2
    Jianbo Dong, Betty C. B. Huang, Bo Wang, Allison Titong, Sachith Gallolu Kankanamalage, Zhejun Jia, Meredith Wright, Pannaga Parthasarathy, Yue Liu · 2020 · Scientific Reports
44. Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS
    Walter Fierz, Brigitte Walz · 2020 · Frontiers in Immunology
45. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina
    D. Ojeda, M. M. Gonzalez Lopez Ledesma, H. Pallarés, Guadalupe S. Costa Navarro, L. Sanchez, B. Perazzi, Sergio M Villordo, D. Álvarez, M. Echavarria, KY Oguntuyo et al. · 2020 · medRxiv
46. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail
    Dong, Jinhui, Zost, Seth J., Greaney, Allison J., Starr, Tyler N., Dingens, Adam S., Chen, Elaine C., Chen, Rita E., Case, James Brett, Sutton, Rachel E., Gilchuk, Pavlo et al. · 2021
47. Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-Infected Syrian Hamsters
    R. Brocato, Lucia M. Principe, Robert K. Kim, Xian-Kun Zeng, Janice A. Williams, Ya-Nan Liu, Rong Li, Jeffrey M. Smith, J. Golden, Dave Gangemi et al. · 2020 · Journal of Virology
48. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies
    M. Finkelstein, Adam G. Mermelstein, Emma Parker Miller, P. Seth, Erik-Stephane D. Stancofski, D. Fera · 2021 · Viruses
49. Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2
    Pedro Alberto Valiente, Han Wen, Satra Nim, JinAh Lee, Hyeon Ju Kim, Jinhee Kim, Albert Perez‐Riba, Yagya Prasad Paudel, Insu Hwang, Kyun‐Do Kim et al. · 2021 · Journal of Medicinal Chemistry
50. Characteristics and serological patterns of COVID ‐19 convalescent plasma donors: optimal donors and timing of donation
    Ling Li, Xunliang Tong, Hanwei Chen, Rui He, Qilu Lv, Ru Yang, Lei Zhao, Jue Wang, Haixia Xu, Chuanqiao Liu et al. · 2020 · Transfusion
51. A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies
    Zhong Yao, Luka Drecun, Farzaneh Aboualizadeh, Sun Jin Kim, Zhijie Li, Heidi Wood, Emelissa J. Valcourt, Kathy Manguiat, Simon W. Plenderleith, Lily Yip et al. · 2021 · Nature Communications
52. Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
    Philip L. Tzou, Kaiming Tao, Janin Nouhin, Soo‐Yon Rhee, Benjamin D Hu, Shruti Pai, Neil T. Parkin, Robert W. Shafer · 2020 · Viruses
53. SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health
    P. Van Caeseele, D. Bailey, Sarah E. D. Forgie, T. Dingle, M. Krajden · 2020 · Canadian Medical Association Journal
54. Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
    Micah Rapp, Yicheng Guo, Eswar R. Reddem, Jian Yu, Lihong Liu, Pengfei Wang, Gabriele Cerutti, Phinikoula S. Katsamba, Jude Saber Bimela, Fabiana A. Bahna et al. · 2021 · Cell Reports
55. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
    Hejun Liu, M. Yuan, De-Li Huang, S. Bangaru, Fang-Zhu Zhao, C. D. Lee, Linghang Peng, Shawn Barman, Xue-Yong Zhu, D. Nemazee et al. · 2021 · Cell Host and Microbe
56. Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies
    Gennady M. Verkhivker, Luisa Di Paola · 2021 · The Journal of Physical Chemistry B
57. A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy
    Allison J. Greaney, Tyler N. Starr, Rachel T. Eguia, Andrea N. Loes, K. Khan, Farina Karim, S. Cele, J. Bowen, Jennifer K. Logue, D. Corti et al. · 2021 · bioRxiv
58. Antibody response patterns in COVID‐19 patients with different levels of disease severity in Japan
    Kazuo Imai, Yutaro Kitagawa, Sakiko Tabata, Katsumi Kubota, Mayu Nagura‐Ikeda, Masaru Matsuoka, Kazuyasu Miyoshi, Jun Sakai, Noriomi Ishibashi, Norihito Tarumoto et al. · 2021 · Journal of Medical Virology
59. A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants
    Yanyun Du, Rui Shi, Ying Zhang, Xiaomin Duan, Li Li, Jing Zhang, Fengze Wang, Ruixue Zhang, Hao Shen, Yue Wang et al. · 2021 · Nature Communications
60. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
    V. Dussupt, R. Sankhala, Letzibeth Mendez-Rivera, Samantha M. Townsley, Fabian Schmidt, L. Wieczorek, Kerri G. Lal, G. Donofrio, Ursula Tran, Nathaniel D. Jackson et al. · 2021 · Nature Immunology
61. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain
    Ling Niu, Kathryn N. Wittrock, Gage C. Clabaugh, Vikram Srivastava, Michael W. Cho · 2021 · Frontiers in Immunology
62. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects
    Jiaxin Zheng, Yingying Deng, Zhenyu Zhao, Binli Mao, Meng-Ji Lu, Yong Lin, Ai-long Huang · 2021 · Cellular & Molecular Immunology
63. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
    Xiaojing Chi, Xinhui Zhang, Shengnan Pan, Yanying Yu, Yujin Shi, Tianli Lin, Huarui Duan, Xiuying Liu, Wenfang Chen, Xuehua Yang et al. · 2022 · Signal Transduction and Targeted Therapy
64. A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus
    Bronwyn M. Gunn, Richard Lu, Matthew D. Slein, Philipp A. Ilinykh, Kai Huang, Caroline G. Atyeo, Sharon L. Schendel, Jiyoung Kim, Caitlin J. Cain-Trivette, Vicky Roy et al. · 2020 · Immunity
65. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates
    Da-Peng Li, R. Edwards, K. Manne, David R. Martinez, A. Schäfer, S. Alam, K. Wiehe, Xiao-Zhi Lu, Robert Parks, Laura L. Sutherland et al. · 2021 · bioRxiv
66. COVID-19 update: The race to therapeutic development
    Julianne D. Twomey, Shen Luo, Alexis Q. Dean, William P. Bozza, Ancy D. Nalli, Baolin Zhang · 2020 · Drug Resistance Updates
67. Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo
    Zhaoyong Zhang, Eric Zeng, Lu Zhang, Weiming Wang, Yingkang Jin, Jiye Sun, Shuxiang Huang, Wenguang Yin, Jun Dai, Zhen Zhuang et al. · 2021 · Cell Discovery
68. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
    K. Vanshylla, Chengcheng Fan, Marie Wunsch, N. Poopalasingam, M. Meijers, C. Kreer, Franziska Kleipass, D. Ruchnewitz, M. Ercanoglu, H. Gruell et al. · 2021 · Cell Host and Microbe
69. SARS-CoV-2 structural features may explain limited neutralizing-antibody responses
    Martin F. Bachmann, Mona Omar Mohsen, Lisha Zha, Monique Vogel, Daniel E. Speiser · 2021 · npj Vaccines
70. COVID-19: Immunology, Immunopathogenesis and Potential Therapies
    Asha Bhardwaj, Leena Sapra, Chaman Saini, Zaffar Azam, Pradyumna Kumar Mishra, Bhupendra Verma, Gyan C. Mishra, Rupesh Kumar Srivastava · 2021 · International Reviews of Immunology
71. Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses
    B. B. Banach, G. Cerutti, A. Fahad, Chen-Hsiang Shen, Matheus Oliveira de Souza, P. Katsamba, Y. Tsybovsky, Pengfei Wang, M. Nair, Yao-Xing Huang et al. · 2021 · Cell Reports
72. Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review
    Daniele Focosi, Fabrizio Maggi, Massimo Franchini, Scott A. McConnell, Arturo Casadevall · 2021 · International Journal of Molecular Sciences
73. A Narrative Review of COVID-19 Vaccines
    Barbaros Eroglu, Rina Fajri Nuwarda, Iqbal Ramzan, Veysel Kayser · 2021 · Vaccines
74. Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2
    Shibo Jiang, Xiujuan Zhang, Lanying Du · 2020 · Expert Opinion on Therapeutic Targets
75. Transmission of SARS-CoV-2 from humans to animals and potential host adaptation
    Cedric C.S. Tan, Su Datt Lam, Damien Richard, Christopher J. Owen, Dorothea Berchtold, Christine Anne Orengo, Meera Surendran Nair, Suresh Varma Kuchipudi, Vivek Kapur, Lucy van Dorp et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
76. Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development
    Yue-Fei Zhu, Jia Li, Z. Pang · 2020 · Asian Journal of Pharmaceutical Sciences
77. Microarray patches enable the development of skin-targeted vaccines against COVID-19
    Emrullah Korkmaz, Stephen C. Balmert, Tina L. Sumpter, Cara Donahue Carey, Géza Erdös, Louis D. Falo · 2021 · Advanced Drug Delivery Reviews
78. Molecular Aspects Concerning the Use of the SARS-CoV‑2 Receptor Binding Domain as a Target for Preventive Vaccines
    Yury Valdés-Balbín, Darielys Santana-Mederos, Françoise Paquet, Sonsire Fernández-Castillo, Yanet Climent, Fabrizio Chiodo, Laura Rodríguez, Belinda Sánchez Ramírez, Kalet León, Tays Hernández et al. · 2021 · ACS Central Science
79. Development and application of therapeutic antibodies against COVID-19
    Lin-jin Ning, H. B. Abagna, Qianhu Jiang, Siqi Liu, Jian Huang · 2021 · International Journal on Biological Sciences
80. Advances in Neutralization Assays for SARS‐CoV‐2
    Yuying Lu, Wang Jin, Qianlin Li, Huan Hu, Jiahai Lu, Zeliang Chen · 2021 · Scandinavian Journal of Immunology
81. Modeling how antibody responses may determine the efficacy of COVID-19 vaccines
    Pranesh Padmanabhan, Rajat Desikan, Narendra M. Dixit · 2022 · Nature Computational Science
82. Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response
    Thayne H. Dickey, Wai Kwan Tang, Brandi Butler, Tarik Ouahes, Sachy Orr-Gonzalez, Nichole D. Salinas, Lynn Lambert, Niraj Harish Tolia · 2022 · Science Advances
83. Understanding COVID-19 in children: immune determinants and post-infection conditions
    Gioacchino Andrea Rotulo, Paolo Palma · 2023 · Pediatric Research
84. Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization
    Shiho Chiba, Steven J. Frey, Peter Halfmann, Makoto Kuroda, Tadashi Maemura, Jie E Yang, Elizabeth Wright, Yoshihiro Kawaoka, Ravi S. Kane · 2021 · Communications Biology
85. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19)
    Feng‐Yee Chang, Hsiang‐Cheng Chen, Pei‐Jer Chen, Mei-Shang Ho, Shie-Liang Edmond Hsieh, Jung‐Chung Lin, Fu‐Tong Liu, Huey‐Kang Sytwu · 2020 · Journal of Biomedical Science
86. Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses
    Jared E. Feldman, Julia Bals, Clara G. Altomare, Kerri St. Denis, Evan Christopher Lam, Blake Marie Hauser, Larance Ronsard, Maya Sangesland, Thalia Bracamonte Moreno, Vintus Okonkwo et al. · 2021 · Science Immunology
87. Epitope profiling using computational structural modelling demonstrated on coronavirus-binding antibodies
    Robinson, Sarah A., Raybould, Matthew I. J., Schneider, Constantin, Wong, Wing Ki, Marks, Claire, Deane, Charlotte M. · 2021 · PLOS Computational Biology
88. Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa
    Emmanuel Margolin, Wendy A. Burgers, Edward D. Sturrock, Marc Mendelson, Rosamund E. Chapman, Nicola Douglass, Anna‐Lise Williamson, Edward P. Rybicki · 2020 · Nature Reviews Microbiology
89. Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action
    Somayeh Sadeghi, Sara Soudi, Abbas Shafiee, Seyed Mahmoud Hashemi · 2020 · Life Sciences
90. Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2
    Wael Bahnan, Sebastian Wrighton, Martin Sundwall, Anna Bläckberg, Olivia J. Larsson, Urban Höglund, Hamed Khakzad, Magdalena Godzwon, Maria Walle, Elisabeth Edström Elder et al. · 2022 · Frontiers in Immunology
91. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
    Liu, Jun, Budylowski, Patrick, Samson, Reuben, Griffin, Bryan D., Babuadze, Giorgi, Rathod, Bhavisha, Colwill, Karen, Abioye, Jumai A., Schwartz, Jordan A., Law, Ryan et al. · 2022 · Science Advances
92. Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis
    Reetesh Kumar, Yogesh Srivastava, Pandiyan Muthuramalingam, Sunil Kumar Singh, Geetika Verma, Savitri Tiwari, Nikunj Tandel, Samir Kumar Beura, Abhishek Ramachandra Panigrahi, Somnath Maji et al. · 2023 · Viruses
93. Clinically relevant cell culture models and their significance in isolation, pathogenesis, vaccine development, repurposing and screening of new drugs for SARS-CoV-2: a systematic review
    Subodh Kumar, Phulen Sarma, Hardeep Kaur, Manisha Prajapat, Anusuya Bhattacharyya, Pramod Avti, Nishant Sehkhar, Harpinder Kaur, Seema Bansal, Saniya Mahendiratta et al. · 2021 · Tissue and Cell
94. Cross-immunity between respiratory coronaviruses may limit COVID-19 fatalities
    Yaqinuddin, Ahmed · 2020 · Medical Hypotheses
95. Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-Test Algorithms
    Sarah E. Turbett, Melis N. Anahtar, Anand S. Dighe, Wilfredo F. García-Beltrán, Tyler E. Miller, Hannah Scott, Sienna Durbin, Maheetha C. Bharadwaj, Jason Thomas, Tasos Gogakos et al. · 2020 · Journal of Clinical Microbiology
96. SARS-CoV-2 and influenza: a comparative overview and treatment implications
    Laura D. Manzanares, Oscar Medina Contreras · 2020 · Boletín Médico del Hospital Infantil de México
97. Nicotinic cholinergic system and COVID-19: In silico identification of interactions between α7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins
    George Lagoumintzis, Christos T. Chasapis, N. Alexandris, D. Kouretas, S. Tzartos, E. Eliopoulos, K. Farsalinos, K. Poulas · 2021 · Food and Chemical Toxicology
98. Pattern of circulating SARS‐CoV‐2‐specific antibody‐secreting and memory B‐cell generation in patients with acute COVID‐19
    Maria G. Byazrova, Gaukhar M. Yusubalieva, Anna A. Spiridonova, Grigory Aleksandrovich Efimov, Dmitriy V. Mazurov, Konstantin O. Baranov, Vladimir P. Baklaushev, Alexander V. Filatov · 2021 · Clinical & Translational Immunology
99. Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody
    Ronit Rosenfeld, Tal Noy-Porat, Adva Mechaly, Efi Makdasi, Yinon Levy, Ron Alcalay, Reut Falach, Moshe Aftalion, Eyal Epstein, David Gur et al. · 2021 · Nature Communications
100. Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11
     J. Fedry, Daniel L. Hurdiss, Chunyan Wang, Wen-Tao Li, G. Obal, I. Drulyte, Wenjuan Du, S. Howes, F. V. van Kuppeveld, Friedrich G. Förster et al. · 2021 · Science Advances